Sofinnova Partners raises $815 million for second crossover fund
AI Summary- Sofinnova Partners raised 725 million euros for its second crossover investment fund.
- The fund targets about 15 drugmakers and medical device developers nearing commercialization.
- Sofinnova has already funded CellCentric and Hemab Therapeutics for clinical trials.